Biologics

PreclinicalSmall molecule

SSixth Affiliated Hospital, Sun Yat-sen University

Biologics is one of 51 small molecule programs targeting Psoriatic Arthritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psoriatic ArthritisActive, not recruiting

Psoriatic ArthritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Psoriatic Arthritis

#DrugCompanyPhaseTrials

Bimzelx

UCB

Phase 3

9 2

Skyrizi

AbbVie

Phase 3

8 3

Jyseleca

Gilead

Phase 3

4 4

Taxol

Teva

Phase 3

1 5

Keytruda

Merck & Co.

Phase 3

1 6

Icotyde

Johnson & Johnson

Phase 3

1 7

Xeljanz

PPrism Pharmaceuticals

Phase 3

8 8

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Biologics2 trials

A Clinical Study to Evaluate the Efficacy of Biologics in SpA

Unknown status·TThe University of Hong Kong-Shenzhen Hospital··NCT04399382·40 enrolled

Multi-omics to Predict Responses to Biologics in IBD

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University··NCT05542459·1,050 enrolled

Psoriatic Arthritis1 trial

A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis

Enrolling by invitation·CChao Ji··NCT06686082·150 enrolled

Efficacy and Safety1 trial

Examination of Efficacy and Safety of Baricitinib in RA Patients

Unknown status·SShinshu University·Phase 2·NCT03755466·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Biologics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biologics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biologics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sixth Affiliated Hospital, Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSixth Affiliated Hospital, Sun Yat-sen University

Biologics

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Biologics2 trials

Psoriatic Arthritis1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News